GC Corp. purchased $12.5M of ARTV

GC Corp. purchased 1,085,069 shares of Artiva Biotherapeutics, Inc. (ARTV) at $11.52 ($12.50M total) on 2026-05-11.

Original reporting
SEC EDGAR · GC Corp.
Published May 28, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Bullish
medium confidence
Mentioned
$ARTV
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVBullishLow
01

Why it matters

This is a primary-source ownership change that may modestly support sentiment, but it does not introduce new company-specific fundamentals in the text.

02

Market read

Traders may treat the $12.5M purchase as a mild positive signal, but without accompanying fundamental news it is unlikely to drive a sustained repricing.

03

What to watch

The article lacks context on whether the buyer’s stake was already large, whether there were concurrent sales, and whether the purchase price ($11.52) was influenced by timing or prior trading plans.

Relevance 8/10Novelty 5/10Timing: SEC Form 4 filed 2026-05-28 for a 2026-05-11 purchase

Background

The article is an SEC Form 4 insider transaction disclosure: GC Corp (10% owner) purchased shares of Artiva Biotherapeutics.

Company-level read

Ticker impact

$ARTVBullishMedium confidence
Context

GC Corp, a 10% owner, bought 1,085,069 shares of Artiva Biotherapeutics for about $12.5M via an open-market purchase.

Expected impact

Near-term impact likely limited; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

Form 4 shows a sizable purchase ($12.5M) and no 10b5-1 plan, but the article provides no new business, guidance, or regulatory/clinical event.

Market effects

Minimal, as the disclosure is company-specific and does not indicate sector-wide regulatory or clinical changes.

None indicated; this is a US-listed company insider transaction.

None indicated; no cross-border deal, trial, or regulatory action is described.

Counterpoint

A large shareholder purchase can reflect liquidity management or diversification rather than a bullish view on fundamentals.

Key entities

  • Artiva Biotherapeutics, Inc.

    Subject of the Form 4 insider transaction; shares were purchased by a 10% owner.

  • GC Corp

    Reported open-market purchase of 1,085,069 shares on 2026-05-11, filed 2026-05-28.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Artiva Ends AlloNK Autoimmune Cell Therapy After Two Trial Deaths, One Unexplained, and Cuts 94% of Staff

Artiva Biotherapeutics halted its AlloNK cell therapy trial for autoimmune diseases after two participant deaths, one linked to chemotherapy. The company will cut 94% of its staff and explore strategic options, including a sale or dissolution. AlloNK was tested with rituximab in rheumatoid arthritis and other autoimmune diseases. Artiva reported $319.1 million in cash as of September 30.

$ARTVMed

Jefferies downgrades Artiva Biotherapeutics stock rating to hold

Jefferies downgraded Artiva Biotherapeutics (ARTV) to Hold with a $4.00 price target after the company discontinued its AlloNK program due to safety concerns and lack of long-term efficacy in rheumatoid arthritis patients. The stock is down 31% over the past week. The company is cutting 94% of staff and exploring strategic alternatives, though it has strong short-term liquidity. Analysts have mixed views, with some maintaining bullish ratings and high price targets.

MedAI 8/10

Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Artiva Biotherapeutics is halting its lead cell therapy program, AlloNK, after two patient fatalities in a mid-stage trial and updated clinical data raising concerns about its efficacy. The company will lay off 94% of its staff and has $319.1 million in cash. Analysts note potential implications for Nkarta and Fate Therapeutics, with Nkarta's upcoming data presentation under scrutiny.